What are the risks of formulation changes, and how do you decide?

This guide covers a supplier moving an existing industrial customer from its current product to a new or reformulated one. It does not cover regulatory change filings for medicines, food additives or pesticides, where the regulator's change rules set the route, or a change forced by a ban that leaves no option to stay.

Which conditions decide whether to move a customer to a new formulation?

Four conditions decide whether to move a customer to a new formulation: how fast its effects show at the customer, what a reversal would cost, which approvals name the current product, and which assumptions the customer has confirmed. Speed comes first. An effect that shows within one production run, such as line speed or a viscosity reading at incoming inspection, can be tested before commitment. An effect that shows only after storage, curing, field service or a full maintenance interval cannot, and the decision then rests on assumptions until that time has passed.

Reversal cost comes second. Write down what going back would need: the old raw materials, retained stock of the current product, the customer's approval of the old product and a second plant trial. Approvals come third. In automotive supply chains, the AIAG PPAP manual, 4th edition, lists a material other than the one in the previously approved part as a change that needs customer notification (Accuride Corporation, citing PPAP Table 3.1, 2026), and the same applies in reverse if the customer has to go back.

Assumptions come last. List what the proposal takes for granted about the customer's process and mark each one as confirmed by the customer, taken from records or unconfirmed. The more that stays unconfirmed, the more the decision should lean toward a staged trial.

Which formulation change routes fit which customer cases?

The formulation change route that fits a customer case follows from how late the effects show, how costly a reversal is and how many assumptions the customer has confirmed. The decision table below chooses between a direct switch, a staged trial with stop signals agreed in advance and staying on the current product.

The row that applies most often is the third: when effects show late but a reversal is still possible, move part of the volume in a staged trial with stop signals agreed in advance, and keep the current product available until those signals are passed. A direct switch suits only the cases where a failure would show before the customer ships its own product. Fill in the left column from the confirmed assumptions list, not from the proposal summary, and record in the change record which row was chosen and why, so a later review can check the reasoning.

Why do the results of a formulation change show up late at the customer?

The results of a formulation change show up late at the customer because the conditions that expose a problem, plant scale, the customer's own recipe and time in use, are rarely present in the supplier's lab. Scale is the first gap. A formulation tested successfully in a small laboratory batch "may behave differently in a 5,000-liter reactor or industrial coating line", and changes in viscosity, pump shear, foaming, curing exotherms or filter behavior "can create operational problems that are invisible during early qualification" (Nexdigm, 2026).

The customer's recipe is the second gap. Industrial customers mix, dilute, coat or cure the product with their own materials, so an interaction can appear only in their process. Nexdigm puts it directly: "Chemical customers rarely buy molecules in isolation. They buy inputs that interact with existing recipes" (Nexdigm, 2026).

Time in use is the third gap. An Institute of Food Technologists column describes a fictional case, built from real ones, in which a preservative swap looked minimal until "a few weeks later, the company starts receiving complaints that the bread no longer has the same shelf life" (IFT, 2025). Industrial equivalents include storage stability, corrosion protection and coating durability, which show only after the time the property is meant to last. List each late effect with the date it could first show, so the trial plan covers it.

Why should a formulation change proposal be compared against keeping the current product?

A formulation change proposal should be compared against keeping the current product because the proposal is usually written by the side that gains from the change, and its expected case tends to be optimistic. UK Treasury appraisal guidance treats this as optimism bias, "the proven tendency for appraisals to be over-optimistic about key assumptions" (HM Treasury Green Book, 2026), and always takes the business-as-usual option forward to the shortlist, where "it acts as a benchmark against which other options are compared" (HM Treasury Green Book, 2026).

For a formulation change, the benchmark is the current product with its own risks stated honestly: a raw material that may stop being available, a regulatory change, or a cost trend. Write each option, including staying, in the same four cases: best, base, worst and extreme. The new formulation often wins the base case and loses the worst case, where a late failure at the customer meets a costly reversal.

The comparison also keeps the customer's view in the proposal. The IFT column asks whether customers will leave because of the reformulation, and advises that if the answer becomes "yes or even plausible, it's time to discuss whether the reformulation should continue" (IFT, 2025). Keeping the current product in the comparison makes that question part of the decision rather than an afterthought.

Which assumptions should be confirmed with the customer before a formulation change?

The assumptions to confirm with the customer before a formulation change are the ones the supplier cannot see from its own records: how the customer uses the product, which of its properties the customer relies on, and what the customer's own change process needs. The IFT column advises understanding "the need-to-have attributes your customers are looking for in your product" before reformulating (IFT, 2025), and a converter warns that "Looking at a data sheet is not enough to say whether it's similar enough to replace the original product" (Strouse, 2025).

Confirm and record each item below, marking it as confirmed by the customer, taken from records or unconfirmed:

1. The properties the customer tests at incoming inspection, with its own limits and test methods.

2. Properties the customer relies on that no specification states, such as mixing time, color, odor or cure speed.

3. The customer's process conditions: dilution, temperature, contact materials and equipment.

4. Every approval, specification, filing or label that names the current product.

5. How long the customer's own validation takes, and who signs it off.

6. How much current product the customer holds, and its shelf life.

7. The criteria the customer would use to call the trial a success.

An item left unconfirmed is a risk, and it should appear in the proposal as one.

Which stop signals should be agreed before a formulation change?

The stop signals to agree before a formulation change are measurable results, each with a limit and a checkpoint, at which the trial pauses or reverses without further debate. UK Treasury guidance calls the same idea switching values, "the values that a key assumption would need to change to, in order to make an option no longer value for money" (HM Treasury Green Book, 2026). General Motors requires a supplier's change process to consider a production trial run for every product and process change and to document the trial results (GM IATF 16949 Customer Specific Requirements, October 2025).

Typical stop signals for a staged trial, with limits set from the customer's own records, are:

• An incoming inspection result outside the customer's limit for any lot.

• A drop in line speed, yield or first-pass quality beyond an agreed margin.

• An aging, storage or durability test that falls short of the current product at its checkpoint.

• A complaint from the customer's own customer that traces to the trial lots.

• An unconfirmed assumption that turns out false.

Write who reads each signal, at which checkpoint, and who decides. The IFT column advises teams "do not be afraid to fail the project fast" (IFT, 2025); a stop signal agreed before the trial makes failing fast a procedure instead of an argument.

What does it cost to reverse a formulation change?

Reversing a formulation change costs a second change at the customer, plus whatever the supplier gave up to make the first one. On the customer side, going back to the old product is a change in its own right. Where the customer's approval now names the new formulation, the PPAP manual, 4th edition, again lists a material other than the one in the previously approved part as a change that needs customer notification (Accuride Corporation, citing PPAP Table 3.1, 2026), and Ford requires its approval before any supplier-initiated change is implemented (Ford Customer-Specific Requirements for PPAP, June 2026). In its answer on layout inspection (clause 8.6.2), an IATF FAQ notes that product requalification "would normally imply full validation to all product approval requirements" (IATF, June 2026).

On the supplier side, a reversal needs the old raw materials, a production slot and people who still know the old process. UK Treasury guidance says decision trees can clarify alternatives "where decisions taken are either irrevocable or expensive to reverse" (HM Treasury Green Book, 2026).

Price the reversal before the first lot ships. Keep the old formulation, its raw material approvals and retained samples until every stop signal has passed, and agree with the customer how much current product stays in reserve. A reversal planned in advance costs time; an unplanned one can cost the account.

Who should sign off a customer's move to a new formulation?

A customer's move to a new formulation should be signed off by both sides: the supplier's technical, quality and sales leads, and the customer's quality or process owner who holds the approval. On the supplier side, the change belongs in the change control process. If the site is certified to ISO 9001, use the edition on its certificate; ISO published the sixth edition, ISO 9001:2026, on 16 September 2026, and it includes clause 8.5.6, Control of changes (ISO, 2026).

Bring in the customer's quality contact before the trial plan is final, because the stop signals use its limits and the route depends on its approvals. Bring in a specialist, such as an application engineer for the customer's process or the raw material maker, when a late effect cannot be tested with an accelerated method you trust. Lubinpla's feasibility review takes this decision in the same order: it fixes the decision, the options and the premises first, asks the user about any premise missing from the records, then compares each option, staying on the current product included, by its early signals and reversal cost, and returns a recommendation with the conditions that would change it.